BillionToOne profit margin BLLN

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months: 9.5%
Operating margin, 12 months: 10.9%
Net margin on a year earlier: +24.1 pts
Peer median: 14.1%

Over the twelve months to Jun 30, 2026, BillionToOne kept 9.5% of its revenue as net profit, with an operating margin of 10.9% and a gross margin of 71.3%.

The median for 10 diagnostics and research stocks of a similar size is 14.1%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal year	Net margin	Operating margin	Gross margin
FY2025	2.4%	5.3%	68.3%
FY2024	n/a	n/a	n/a

Quarter by quarter

Quarter	Ended	Net margin, 12 months	Change on a year	Operating margin
Q2 FY26	Jun 30, 2026	9.5%	+24.1 pts	10.9%
Q1 FY26	Mar 31, 2026	8.3%	n/a	10.2%
Q4 FY25	Dec 31, 2025	2.4%	n/a	5.3%
Q3 FY25	Sep 30, 2025	−3.9%	n/a	−2.4%
Q2 FY25	Jun 30, 2025	−14.6%	n/a	−13.5%
Q1 FY25	Mar 31, 2025	n/a	n/a	n/a
Q4 FY24	Dec 31, 2024	n/a	n/a	n/a
Q3 FY24	Sep 30, 2024	n/a	n/a	n/a

Against its peers

Companies in Medical - Diagnostics & Research nearest BillionToOne's size, closest first, today.

Company	Profit margin
BLLNBillionToOne	9.5%
LNTHLantheus	17.7%
VCYTVeracyte	20.4%
CDNACareDx	24.2%
CAICaris Life Sciences	10.6%
BIOBio-Rad Laboratories	8.6%
RVTYRevvity	8.2%
MEDPMedpace	17.7%
LHLabcorp	7.0%
DGXQuest Diagnostics	9.2%
MTDMettler-Toledo International	21.9%
Peer median	14.1%

Where BillionToOne ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on BillionToOne

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.